Long-Term Outcome of Approved Pharmacotherapy for Diabetic Macular Edema: A Review of Randomized Controlled Trials in Fluocinolone Acetonide Implants, Dexamethasone Implants, Aflibercept and Ranibizumab
Journal: Journal of Clinical Research and Ophthalmology (Vol.2, No. 2)Publication Date: 2015-03-01
Authors : Fang-Ting Chen; Jia-Kang Wang;
Page : 015-018
Keywords : ;
Abstract
Diabetic macular edema (DME) is a major sight-threatening cause in diabetic patients. The pathophysiology of macular edema involves both the presence of inflammation and angiogenic stimulant.
Other Latest Articles
- Posterior Polar Hemispheric Choroidal Dystrophy
- Eye Involvement as the Initial Sign of Multiple Sclerosis in a Case with Familial Mediterranean Fever
- Literature Review Paper on Mechanical Properties of Types of Carbon Nanotubes
- Needle Revision with Antimetabolites in Bleb Failure
- Central Corneal Thickness in Nepalese Glaucoma Patients and Glaucoma Suspects
Last modified: 2018-08-28 18:44:52